Interview with Anil Raghavan, Country Head – India, Quintiles India
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
Address: 301 A-Leela Business Park,M.V. Road, Andheri
Mumbai-59,India
Tel: +91 22 5677 4242
Web: http://www.quintiles.com/
Quintiles Transnational is a pharmaceutical services company offering clinical, commercial, consulting and capital services. The Quintiles network consists of more than 20,000 employees in 60 countries.
Quintiles manages clinical trials on behalf of pharmaceutical customers, and provides the following services:
Management of clinical trials, data, projects and providing laboratory services
Providing customers with sales force, product and brand solutions.
Providing data-driven recommendations to help customers achieve success.
Creating strategic partnerships through financing and operational solutions.
Quintiles India is located amidst a rapidly growing local pharmaceutical market. With five offices spread across the country, we help clients take advantage of a well-established corporate infrastructure, government policies favoring R&D, growth in the health insurance sector, and tertiary care and teaching hospitals available for trials.
Other advantages: Quintiles India has solid relationships with leading medical centers and experienced English-speaking investigators. All studies are conducted to FDA and ICH GCP standards. Urban India’s literate population provides fast, efficient access to broad population groups with common and special disease profiles, allowing for rapid patient recruitment and faster study start-ups.
Quintiles helped develop or commercialize all of 2009’s top 50 best selling drugs or compounds and nearly 90% of all breakthrough products released on the market between 1996 and 2008.
Key Services in India:
Access to patients
Biostatistics
Central laboratory services
Clinical monitoring and site management
Data management offering a functional service provider (FSP) business model
Drug safety/pharmacovigilance
ECG monitoring services
Project management
Regulatory services
Phase I/IIa
Access through Our India Team to Quintiles Worldwide:
Consulting services
Partnering
Quintiles first established its operations in India in 1997, which was a very early stage in clinical research. What have been the main changes undergone by the country since then?…
If we look back at the conditions under which you founded Biocon in 1978, we see a young woman with a seed capital of only Rs. 10,000 in a garage…
You have already publicly announced that, despite being late in India, Lonza has been increasingly looking into expanding in the Indian market. First of all, what do you think sparked…
Before moving into the company’s strategy, can you give our readers an idea of what role Boehringer Ingelheim India plays within the Group’s worldwide operations? Within the Boehringer Ingelheim Group,…
To start off, can you tell us how you have seen the pharmaceutical industry developing in India? Has the perception of India by big pharma changed over the years? First…
A catalyst of India’s shifting industry dynamics has been the sector’s M&A activity. We already saw majors such as Piramal going to Abbott and Ranbaxy to Daiichi-Sankyo… And while Andrew…
With the recent event “Vibrant Gujarat”, the state of Gujarat aimed to showcase the region’s opportunities and advanced infrastructure, hosting 1,400 delegates from 101 countries as well as several presentations…
You founded Calyx in 1979 with a three-person team. At the time, you were just 21 years old! What was the vision behind the creation of the company? Essentially, the…
You joined Wockhardt in 2000; you became a member of the board in 2006, and were appointed managing director in 2009. The Indian industry has undergone many changes in the…
Glenmark may be poised to release India’s first novel drug, from the in-licensed, anti-diarrheal molecule Crofelemer. Crofelemer has successfully complete Phase III trials, and you are readying to release it…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Since we last met in 2006, the Indian pharmaceutical industry has been doing very well indeed, as a very large number of drugs came off patent. This trend will continue…
Our last report on India dates back to 2006, right after the Patent Law was passed. What developments have you seen happening in the industry since then? There has been…
See our Cookie Privacy Policy Here
